Researchers have substantially advanced its progress of an novel therapy for ATTR-CM, utilizing the compound. Initial trial information reveals potential benefits for individuals affected by the serious disease. The effort highlights BridgeBio's dedication to addressing significant medical requirements in a cardiology arena. Attruby: BridgeBio's N